109 related articles for article (PubMed ID: 162366)
1. Carcinogenic activity in Sprague-Dawley rats of 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-gluco-pyranose (chlorozotocin).
Habs M; Eisenbrand G; Schmähl D
Cancer Lett; 1979 Dec; 8(2):133-7. PubMed ID: 162366
[TBL] [Abstract][Full Text] [Related]
2. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity.
Anderson T; McMenamin MG; Schein PS
Cancer Res; 1975 Mar; 35(3):761-5. PubMed ID: 123170
[TBL] [Abstract][Full Text] [Related]
3. Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro.
Lam HY; Talgoy MM; Goldenberg GJ
Cancer Res; 1980 Nov; 40(11):3950-5. PubMed ID: 6451281
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat.
Fiebig HH; Eisenbrand G; Zeller WJ; Zentgraf R
Oncology; 1980; 37(3):177-83. PubMed ID: 6444708
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of chlorozotocin and BCNU on hematopoietic precursor cells.
Horikoshi A; Smith R; Murphy MJ
Chemotherapy; 1983; 29(2):135-44. PubMed ID: 6220871
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose.
Nagourney RA; Fox P; Schein PS
Cancer Res; 1978 Jan; 38(1):65-8. PubMed ID: 145314
[TBL] [Abstract][Full Text] [Related]
7. Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity.
Fox PA; Panasci LC; Schein PS
Cancer Res; 1977 Mar; 37(3):783-7. PubMed ID: 138478
[TBL] [Abstract][Full Text] [Related]
8. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Moertel CG; Lefkopoulo M; Lipsitz S; Hahn RG; Klaassen D
N Engl J Med; 1992 Feb; 326(8):519-23. PubMed ID: 1310159
[TBL] [Abstract][Full Text] [Related]
9. Chlorozotocin.
Rep Carcinog; 2004; 11():III62-3. PubMed ID: 21089833
[No Abstract] [Full Text] [Related]
10. Enhanced cloning efficiency of murine rhabdomyosarcoma cells after chlorozotocin treatment: relationship with enhanced lung metastasis.
Pauwels C; Rebischung JL; Jasmin C; Poupon MF
J Natl Cancer Inst; 1985 Apr; 74(4):817-20. PubMed ID: 3157818
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on the antitumor activity and the bone marrow toxicity of 1-(beta-D-glucopyranosyl)-3-(2-chloroethyl)-3-nitrosourea and 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose.
Aoshima M; Sakurai Y
Gan; 1977 Apr; 68(2):247-50. PubMed ID: 892299
[TBL] [Abstract][Full Text] [Related]
12. Increased mutagenicity of chloroethylnitrosoureas in the presence of a rat liver S9 microsome mixture.
Suling WJ; Rice LS; Shannon WM
J Natl Cancer Inst; 1983 Apr; 70(4):767-9. PubMed ID: 6220173
[TBL] [Abstract][Full Text] [Related]
13. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
Panasci LC; Green D; Schein PS
J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of 3-[3-(2-chloroethyl)-3-nitrosoureido]-3-deoxy-D-glucopyranose on murine tumors.
Komiyama K; Edanami K; Kuroda T; Umezawa I
Gan; 1981 Feb; 72(1):53-9. PubMed ID: 6456168
[TBL] [Abstract][Full Text] [Related]
15. Cholestatic jaundice associated with chlorozotocin.
Belt RJ; McGregor D; Haas CD; Bhatia PS
Cancer Treat Rep; 1980; 64(12):1235-9. PubMed ID: 6451288
[TBL] [Abstract][Full Text] [Related]
16. Examination of four newly synthesized 2-chloroethylnitrosoureas in comparison with BCNU, CCNU, MeCCNU, chlorozotocin and hydroxyethyl-CNU in preterminal rat leukemia L 5222.
Zeller WJ; Eisenbrand G; Fiebig HH
J Cancer Res Clin Oncol; 1979 Sep; 95(1):43-9. PubMed ID: 159309
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
Macdonald JS; Hoth D; Schein PS
Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary disease as a complication of chlorozotocin chemotherapy.
Ahlgren JD; Smith FP; Kerwin DM; Sikic BI; Weiner JH; Schein PS
Cancer Treat Rep; 1981; 65(3-4):223-9. PubMed ID: 6453644
[TBL] [Abstract][Full Text] [Related]
19. Nitrosourea chemotherapeutic agents: Chlorozotocin.
National Toxicology Program
Rep Carcinog; 2011; 12():328-9. PubMed ID: 21860521
[No Abstract] [Full Text] [Related]
20. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
